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Background: The ErbB family consists of four proteins including (EGFR)/ErbB1, ErbB2, ErbB3, and ErbB4, and plays a
crucial role in the promotion of multiple tumorigenic processes. In addition to the traditional pathways of EGFR
signaling, EGFR translocates to the nucleus and acts as a transcription factor in the proliferation of cancer cells.
Heregulin is known as both an ErbB3 and an ErbB4 ligand. This study aimed to investigate the expression of
heregulin and its relevant EGFR family members as well as their phosphorylated forms in human colorectal
cancer (CRC) tissues and to determine the relationship between their expression and clinicopathological factors
including patient prognosis.
Methods: We analyzed the effects of exogenous heregulin on ErbB2, ErbB3 and ErbB4 phosphorylation in Caco-2,
DLD-1, and HCT 116 colon cancer cell lines by western blot analysis. We examined 155 surgical resections from
colorectomy patients. Cellular localization of ErbB1-4, their phosphorylated forms and heregulin protein was analyzed
in CRC surgical resections by immunohistochemical analysis. Immunohistochemical results were compared with
clinicopathological factors and patient prognosis.
Results: Phosphorylated ErbB2 (pErbB2) and phosphorylated ErbB3 (pErbB3) were detected in both nuclear and
cytosolic fractions of Caco-2 and DLD-1 cells stimulated by exogenous heregulin. Whereas, phosphorylated ErbB4
(pErbB4) was detected only in cytosolic fractions of HCT 116 cells stimulated by exogenous heregulin. Phosphorylated
EGFR (pEGFR) immunoreactivity was observed in the cytoplasm and nuclei of cancer cells, whereas the pattern of EGFR
staining was membranous and cytoplasmic. Subcellular localization of pErbB2, cytoplasmic, membranous, or nuclear,
varied among cases. pErbB3 immunoreactivity was exclusively observed in the nuclei of cancer cells. pErbB4
immunoreactivity was observed in the cell membrane of cancer cells. Statistically, heregulin immunoreactivity
correlated with pErbB2 and pErbB4 expression. In multivariate analysis for disease free survival, lymph node status,
pErbB3 and pErbB4 expression retained independent prognostic significance. In multivariate analysis for overall
survival, lymph node status, pEGFR and pErbB4 retained independent prognostic significance.
Conclusions: ErbB2 and ErbB3 phosphorylated by heregulin localized in the nucleus of CRC cells. Phosphorylated
ErbB1-4 and heregulin contribute to poorer patient prognosis in CRC. This heregulin-ErbB family member autocrine loop
may be a candidate for targeted treatment of CRC.
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The epidermal growth factor receptor (EGFR) family
consists of four receptors; ErbB1/HER1/EGFR, ErbB2/
HER2, ErbB3/HER3, and ErbB4/HER4, and belongs to
the superfamily of type I receptor tyrosine kinases. The
EGFR and all other family members contain an extra-
cellular ligand-binding domain (except in the case of
ErbB2), a transmembrane region and a cytoplasmic do-
main with kinase activity [1,2]. Activation of EGFR re-
ceptors by the binding of the cognate ligands induces
formation of homo- and hetero-dimers between differ-
ent members of the EGFR family, and subsequent phos-
phorylation of specific sites in the cytoplasmic tail and
recruitment of protein adaptors results in activation of
multiple downstream signaling pathways. ErbB recep-
tors have been studied for their use as potential prog-
nostic markers and therapeutic targets [3,4].
Colorectal cancer (CRC) remains a significant cause of
morbidity and mortality throughout the world [5,6]. The
low molecular weight tyrosine kinase inhibitors and the
monoclonal antibodies against EGFR are in clinical de-
velopment and have shown clinical benefit in metastatic
CRC [7,8]. EGFR and ErbB2, two of four members of
the EGFR tyrosine kinase family, have been widely stud-
ied on CRC [4]. In contrast, the remaining members of
the family, ErbB3 and ErbB4, have been largely ignored
by clinical studies targeting CRC [4]. It has been re-
ported that intestine-specific ErbB3 ablation resulted in
almost complete absence of intestinal tumors in the
ApcMin mouse model of colon cancer and that ErbB3-
ErbB4 heterodimers contribute to colon cancer survival
[9]. Nevertheless, the relationship between the expres-
sion of these proteins and clinicopathological factors,
as evaluated by immunohistochemical techniques, has
proven to be controversial in those studies [4].
In addition to the traditional pathways of EGFR sig-
naling, several studies have reported that EGFR translo-
cates to the nucleus and acts as a transcription factor
in the proliferation of normal and cancer cells alike
[10,11]. For example, nuclear EGFR has been detected
in a number of human cancers including breast, oro-
pharyngeal, bladder, pancreatic, ovarian, lung and colo-
rectal [12-14], and nuclear EGFR has been associated
with acquired resistance to chemotherapy and poor
prognosis [15-17]. On the other hand, there have only
been a few studies concerning the clinical significance
of nuclear or phosphorylated EGFR family members in
human CRC.
The identities of the activating ligand and the hetero-
dimer partner are the most important factors in deter-
mining which pathway is activated. The ErbB2-ErbB3
hetero-dimer is considered the most potent ErbB pair
with respect to strength of interaction, ligand-induced
tyrosine phosphorylation and downstream signaling, andfunctions as an oncogenic unit [18,19]. Heregulin is a
member of the EGF-family peptides and is known as
both an ErbB3 and an ErbB4 ligand [20]. Interaction of
heregulin with the dimers of its receptors, including
ErbB3 and ErbB4, results in various biological functions.
To date, most studies have shown that heregulin exhibits
a growth-stimulatory effect in a variety of cancer cells,
including breast cancer cells and colorectal cancer cells
[21,22]. Previously we have shown that heregulin may
contribute to angiogenesis through the phosphorylation
of ErbB3 in colon cancer cell lines [23]. However, there
have been scant reports regarding the relationship be-
tween heregulin expression and clinicopathological fac-
tors including patient prognosis, and the relationship
between each member of the EGFR family and heregulin
in human CRC [24].
This study aimed to investigate the expression of here-
gulin and its relevant EGFR family members, EGFR,
ErbB2, ErbB3 and ErbB4, and their phosphorylated forms,
in human CRC tissues and to determine the relationship




Recombinant human heregulin-β1 EGF domain (rHRG)
was purchased from R&D System Inc. (Minneapolis,
MN.). The list of primary antibodies used in this study is
shown in Additional file 1: Table S1. Of these, anti-EGFR
antibody (clone EGFR.25; Leica biosystems/Novocastra) is
raised to the cytoplasmic domain of the EGFR molecule.
Anti-ErbB2 antibody (Dako) is raised to the cytoplasmic
domain of the ErbB2 molecule. Anti-ErbB3 antibody
(abcam) is a synthetic peptide corresponding to an in-
ternal sequence of ErbB3. Anti-ErbB4 antibody (Thermo
scientific) immunogen is a C-terminus of human ErbB4.
Cell culture
The human colorectal cancer cell lines Caco-2, DLD-1
and HCT 116 cells were routinely grown according to
the supplier’s instructions, supplemented with 10% fetal
calf serum.
Immunoprecipitation and Western blot analysis
Colon cancer cells were starved in serum-free medium
overnight before rHRG treatment. Then, cells were incu-
bated with or without 100 ng/mL rHRG for 1 h at 37°C.
Nuclear extracts were obtained according to Schreiber
et al. [25]. Typically, 1 × 106 cells from cultured cell lines
were washed with 10 mL cold PBS and pelleted by cen-
trifugation at 1500 g for 5 min. The pellet was resus-
pended in 1 mL PBS, and pelleted again by spinning for
3 min in a microfuge. PBS was removed and the cell pel-
let resuspended in 400 μL cold buffer A (10 mM HEPES
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1 mM DTT; 0.5 mM PMSF; 1 mM Vanadate) on ice for
15 min, after which 25 μL of a 10% solution of NP-40
was added and the tube vortexed for 10 sec. The tube
was then centrifuged at 500 g for 3 min and the non-
nuclear fraction obtained from the supernatant. The
nuclear pellet was resuspended in 200 μL ice-cold
buffer B (20 mM HEPES pH 7.9; 0.4 M NaCl; 1 mM
EDTA; 1 mM EGTA; 1 mM DTT; 1 mM PMSF; 1 mM
Vanadate) at 4°C for 15 min. The tube was then centri-
fuged at 15000 rpm for 15 min at 4°C and the nuclear
fraction obtained from the supernatant. The nuclear frac-
tions were normalized by total protein amount (1 mg)
before immunoprecipitation. One mg protein samples
were incubated with 3 μg of anti-phosphotyrosine anti-
body (PY-20; Santa-Cruz, CA) immobilized onto protein
G-Sepharose for 4 h at 4°C. Immunoprecipitates were
washed thrice with washing buffer (50 mM HEPES
(pH 7.6), 150 mM NaCl, 0.1% Triton X-100) and boiled
5 min in SDS sample buffer. The samples were separated
by 10% SDS-polyacrylamide gel electrophoresis and
transferred to a PVDF membrane. The transferred pro-
teins were probed with specific antibodies against ErbB2
(C-18; Upstate, NY), ErbB3 (C-17; Santa-Cruz, CA) and
pErbB4 (Tyr1162; Cell Applications inc., San Diego, CA)
for 1 h at 25°C. After washing, protein signals were de-
tected with horseradish peroxidase-conjugated antibody
against the appropriate IgG using enhanced chemilumin-
escence detection.
Patients and tissue samples
We obtained 155 colon and rectum adenocarcinoma
tissue samples from archives of the Department of
Pathology at Nippon Medical School Hospital for im-
munohistochemical analysis of heregulin, EGFR, ErbB2,
ErbB3, ErbB4, pEGFR, pErbB2, pErbB3 and pErbB4
protein expression. Patients included 90 men and 65
women ranging in age from 44 to 91 years (average age,
66.1 years; median, 66.0 years). We excluded patients
who had undergone chemotherapy or radiation. Patients
were traced via hospital and pathology records from 1996
to 2006. Disease free survival (DFS) was defined as the
interval from the date of the first surgery until relapse,
the appearance of a second primary cancer, or death,
whichever occurred first. At the time of analysis, 47 pa-
tients had died, and 108 still survived. The median
follow-up time for the whole series was 42 months
(mean, 46 months; range, 3 to 111 months) and the me-
dian survival 62 months (mean, 56 months; range, 3 to
111 months). All subjects gave informed consent, and the
project was approved by the Ethics Committee of Nippon
Medical School. All staging criteria were defined accord-
ing to the International Union Against Cancer TNM
classifications.Immunohistochemical analysis
Specimens were fixed in 10% formalin, embedded in
paraffin wax, cut into 4 μm sections, and immersed in
0.3% H2O2–methanol for 30 min to block endogenous
peroxidase activity. Sections were then microwaved in
0.01 mol/l citrate phosphate buffer (pH 6.0) or EDTA
(pH9.0) for antigen retrieval and incubated with 10%
normal horse or goat serum for 10 min at 37°C to
block nonspecific immunoglobulin (IgG) binding. There-
after, sections were incubated for 18 h at 4°C with
anti-heregulin, anti-EGFR, anti-pEGFR, anti-ErbB2, anti-
pErbB2, anti-ErbB3, anti-pErbB3, anti-ErbB4, or anti-
pErbB4 antibodies. They were then treated with their
respective biotinylated antibodies; namely, anti-mouse
IgM, anti-mouse IgG, or anti-rabbit IgG (1:200) for 1 h at
25°C, followed by treatment with avidin-biotin peroxidase
complex for 1 h at 25°C. The reaction products were devel-
oped by immersing sections in 3,3′-diaminobenzidine tet-
rahydrochloride solution containing 0.03% H2O2. Nuclei
were counterstained with Mayer’s hematoxylin.
Evaluation of immunohistochemical staining
Each case was evaluated blindly by two independent
observers (K.M. and A.T.). Any disagreement was re-
solved using a multi-headed microscope (kw, Heregulin =
85%; kw, EGFR = 80%; kw, ErbB2 = 82%; kw, ErbB3 = 90%;
kw, ErbB4 = 88%; kw, pEGFR = 82%; kw, pErbB2 =
78%; kw, pErbB3 = 90%; kw, pErbB4 = 82%). Cases
showing heregulin or ErbB3 immunostaining were
scored using the following scoring system adopted by
Rajkumar, resulting from the product of the score for
the fraction of positive cells (range, 0 to 4 [0, <10%
positively stained cells; 1, 10% to 25%; 2, 26% to 50%; 3,
51% to 75%; and 4, >75%]) and the score for staining in-
tensity (range, 0 to 3). Slices with scores of 8 or higher
were classified as positive and slices with scores lower
than 8 as negative. EGFR, ErbB2, ErbB4 or pErbB4 stain-
ing was scored semi-quantitatively according to the follow-
ing scoring system approved by the US Food and Drug
Administration [26]: 0, no immunostaining or membrane
staining in <10% of the tumor cells; 1+, incomplete
membrane staining of >10% of tumor cells; 2+, weak-to-
moderately complete membrane staining of >10% of tumor
cells; 3+, moderate-to-strongly complete membrane stain-
ing of >10% of tumor cells. Scores of 0 or 1+ indicated
tumor negative, and scores of 2+ and 3+ were regarded as
positive expression of EGFR, ErbB2, ErbB4, and pErbB4.
Subcellular localization of pErbB2 varied among cases;
cytoplasmic, membranous, or nuclear. Cases showing
pErbB2 immunoreactivity in >10% percent of cancer
cells were regarded as positive irrespective of subcellular
localization. Subcellular localization of pErbB3 was ex-
clusively in the nucleus. There was no variation in the
intensity of nuclear staining and only cases with more
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were considered positive.
Statistical analysis
Immunostaining results for each protein were compared
with clinicopathological factors including age, gender,
location, vessel invasion, node metastasis, depth of inva-
sion, and stage, using the chi-square test or Fisher’s
exact test as appropriate. The association among each
protein immunostaining was also assessed by the chi-
square test or Fisher’s exact test as appropriate. The
distribution of disease free survival was estimated by
Kaplan-Meier methodology, and the log-rank test was
used to test for significant differences in disease free sur-
vival. A Cox proportional hazard model was used to as-
sess the effect of tumor variables on overall survival. In
multivariate analysis, variables with P < 0.05 in the




Previously, we examined the effects of rHRG on tyrosine
phosphorylation of ErbB proteins in cytosolic fractions
of colon cancer cell lines [23]. In this study we examinedFigure 1 The effects of exogenous heregulin on tyrosine phosphoryla
fractions of colon cancer cell lines. After heregulin treatment, the cells
phosphotyrosine (PY-20). Immunoprecipitates were analyzed by Western blot
pErbB3 were detected in both the nuclear and cytosolic fractions of both DLD
increased with exogenous heregulin stimulation in only the cytosolic fractionsthe effects of rHRG on tyrosine phosphorylation of the
ErbB2, ErbB3, and ErbB4 proteins in nuclear fractions of
colon cancer cell lines.
After immunoprecipitation with an antibody against
phosphotyrosine (PY-20), western blot analyses revealed
that both the DLD-1 and Caco-2 cell lines express a pro-
tein with a molecular weight of approximately 180 kD
reacting against antibodies to the ErbB2 (C-18) and
ErbB3 (C-17) proteins (Figure 1A). Although ErbB2
phosphorylation was observed under basal conditions,
exogenous rHRG further stimulated ErbB2 in both the
nuclear and cytosolic fractions of DLD-1 cells. On the
other hand, pErbB2 was detected in the nuclear fraction
of Caco-2 cell only after rHRG treatment. The same was
true for the expression of pErbB3 in DLD-1 and Caco-2
cells, where pErbB3 was detected in both the nuclear and
cytosolic fractions following cellular exposure to rHRG.
These results suggest that exogenous rHRG stimulated
ErbB2 and ErbB3 phosphorylation in the nuclear frac-
tions of both DLD-1 and Caco-2 cells. The limitation of
this study revolves around the fact that calculation of the
relative amounts of pErbB2 and pErbB3 in the cytoplasm
and nuclear fractions in cancer cell lines is not warranted
given the data. Prior to immunoprecipitation, the nu-
clear and cytoplasmic fractions of cancer cell linestion of ErbB2, ErbB3 and ErbB4 in both the cytosolic and nuclear
were lysed and immunoprecipitated with an antibody against
ting with anti-phosphorylated ErbB receptor antibodies. A, pErbB2 and
-1 and Caco-2 cells after heregulin stimulation. B, ErbB4 phosphorylation
of HCT 116 cells.
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than by the number of cell equivalents of each fraction.
ErbB4 was not detected in any fractions in DLD-1 or
Caco-2 cells (data not shown) [23]. Therefore, our
present study used the HCT 116 cell line to detect
ErbB4 according to Xu et al. [27]. After immunoprecipita-
tion by PY-20, a western blot analysis using an antibody
against ErbB4 (Tyr1162) revealed a band of approximately
180 kD in the cytosolic fraction of HCT 116 cells in the ab-
sence of rHRG stimulation. ErbB4 phosphorylation in-
creased with rHRG stimulation in the cytosolic fractions of
HCT 116 cells. ErbB4 was nearly absent in the nuclear
fractions of HCT 116 cell regardless of ligand stimulation
(Figure 1B). This suggests that although heregulin stimu-
lates ErbB4 phosphorylation on the cell membrane, pErbB4
fails to translocate into the nucleus.
Heregulin, ErbB1-4, and pErbB1-4 localization in
colorectal cancer
We next examined localization of heregulin, EGFR, ErbB2,
ErbB3, ErbB4, pEGFR, pErbB2, pErbB3 and pErbB4 pro-
teins by immunohistochemical analysis.
Heregulin immunoreactivity was predominantly ob-
served in the cytoplasm of cancer cells in 72 cases (46%;
31% with score 8, 9% with score 9 and 6% with score 12)
(Figure 2A). Heregulin expression was weak-to-absent in
stromal cells, including fibroblasts, but was nearly absent
in glandular epithelial cells of colorectal mucosa adjoin-
ing cancer tissue.
EGFR immunoreactivity was observed in cancer cells in
79 cases (51%; 40% with score 2+ and 10% with score 3+).
The predominant pattern of EGFR staining was membran-
ous and cytoplasmic (Figure 2B). pEGFR immunoreactivity
was observed in the cytoplasm and nuclei of cancer cells in
50 (32%) cases (Figure 2C). EGFR and pEGFR were nearly
absent in glandular epithelial cells of colorectal mucosa
adjoining cancer tissue.
ErbB2 immunoreactivity was observed in cancer cells in
41 cases (26%; 16% with score 2+ and 10% with score 3+).
The predominant pattern of ErbB2 staining was in the
membrane (Figure 2D); a few tumors showed only cyto-
plasmic staining but these cases were considered negative
according to the evaluation method followed. Subcellular
localization of pErbB2 varied among cases; cytoplasmic
(Figure 2E), membranous (Figure 2F), and/or nuclear
(Figure 2G). When considering pErbB2 immunoreactivity
as positive irrespective of subcellular localization, 30 (19%)
cases were found to be positive for pErbB2, 21 (14%) cases
were cytoplasmic, 1 (1%) case was membranous and 8 (5%)
cases were nuclear. ErbB2 and pErbB2 were nearly absent
in glandular epithelial cells of colorectal mucosa adjoining
cancer tissue.
ErbB3 immunoreactivity was predominantly observed
in the cytoplasm and membrane of cancer cells in 64(41%) cases (Figure 2H), whereas pErbB3 immunoreac-
tivity was exclusively observed in the nuclei of cancer
cells in 40 (26%) cases (Figure 2I). ErbB3 and pErbB3
were nearly absent in glandular epithelial cells of colo-
rectal mucosa adjoining cancer tissue.
ErbB4 and pErbB4 immunoreactivity was observed in
cancer cells in 33 (21%) and 25 (16%) cases, respectively
(Figure 2J,K). The predominant pattern of ErbB4 and
pErbB4 staining was membranous with or without cyto-
plasmic expression. ErbB4 and pErbB4 were nearly ab-
sent in glandular epithelial cells of colorectal mucosa
adjoining cancer tissue.
Relationship between heregulin, ErbB1-4, pErbB1-4 and
clinicopathological factors
We then explored the clinical significance of the protein
expression of these receptors and heregulin in CRC. For
tumors that were considered as positive irrespective of
the subcellular localization of each protein, the relation-
ship with clinicopathological factors was analyzed statis-
tically in Table 1.
Positive rates for each heregulin, pEGFR, ErbB2, pErbB2,
and ErbB3 immunostaining increased significantly with
invasion depth. Positive rates for EGFR, pEGFR, ErbB2
and pErbB3 immunostaining increased significantly with
advancing stage. Heregulin and, with the exception of
ErbB3, EGFR family member immunoreactivities corre-
lated with liver metastasis (the case of pErbB4 was border-
line; P value = 0.057).
Each phosphorylated ErbB receptor immunoreactivity
correlated with the corresponding ErbB receptor; namely,
pEGFR correlated with EGFR (Additional file 2: Table S2).
Since heregulin induces ErbB2 phosphorylation via both
ErbB3 and ErbB4 phosphorylation, heregulin expression
was predicted to correlate with the expression of all three
phosphorylated forms, pErbB2, pErbB3 and pErbB4.
However, although heregulin immunoreactivity corre-
lated with pErbB2 and pErbB4, no correlation was found
with pErbB3 expression. Instead, EGFR and pEGFR were
found to correlate with pErbB2, pErbB3 and pErbB4. In
addition, pErbB2 correlated with pErbB3 and pErbB4
(Additional file 2: Table S2). This stands to reason be-
cause pErbB2 can be induced via either ErbB3 or ErbB4
phosphorylation.
Comparative survival analysis
Finally, we explored the relationship between clinico-
pathological factors and each protein expression, and pa-
tient prognosis of CRC.
Survival analysis was performed on 95 stage II-III pa-
tients for disease free survival; stage I patients were
omitted since none of the stage I patients had died dur-
ing the follow-up time. In univariate analysis using the
Cox proportional hazards model for disease free survival,
Figure 2 Immunohistochemical localization of heregulin (A), EGFR (B), pEGFR (C), ErbB2 (D), pErbB2 (E-G), ErbB3 (H), pErbB3 (I), ErbB4
(J), and pErbB4 (K) in colorectal adenocarcinoma. A, Heregulin was stained in the cytoplasm of adenocarcinoma cells. 40x B, EGFR was
stained in the cell membrane and cytoplasm of adenocarcinoma cells. 20x, Insert; EGFR in the cell membrane. 60x C, pEGFR was stained in the
nucleus of adenocarcinoma cells. 20x, Insert; pEGFR in the cell membrane and cytoplasm. 60x D, ErbB2 was stained in the cell membrane of
adenocarcinoma cells. 40x E, pErbB2 was stained in the cytoplasm of adenocarcinoma cells. 40x F, pErbB2 was stained in the cell membrane of
adenocarcinoma cells. 40x G, pErbB2 was stained in the nucleus of adenocarcinoma cells. 40x H, ErbB3 was stained in the cell membrane and
cytoplasm of adenocarcinoma cells. 20x, Insert; ErbB3 in the cell membrane. 60x I, pErbB3 was stained in the nucleus of adenocarcinoma cells.
40x J, ErbB4 was stained in the cell membrane of adenocarcinoma cells. 40x K, pErbB4 was stained in the cell membrane of adenocarcinoma
cells. 40x.
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pErbB3, ErbB4 and pErbB4 each had significant prog-
nostic value (Table 2). However, in multivariate ana-
lysis performed by introducing all the above variables
in the Cox proportional hazards model, lymph nodestatus, pErbB3 and pErbB4 expression retained inde-
pendent prognostic significance (Table 2).
Survival analysis was performed on 155 stage I-lV pa-
tients for overall survival. In univariate analysis using the
Cox proportional hazards model for overall survival,
Table 1 Relationship between heregulin, ErbB1-4, pErbB1-4 and clinicopathological factors





















<66 78 38 (49) NS 46 (59) NS 27 (35) NS 14 (18) 0.018 12 (15) NS 28 (36) NS 19 (24) NS 17 (22) NS 9 (12) NS
≥66 77 33 (43) 33 (43) 23 (30) 27 (35) 18 (23) 36 (47) 21 (27) 16 (21) 16 (21)
Gender
Male 90 41 (46) NS 45 (50) NS 26 (29) NS 27 (30) NS 20 (22) NS 41 (46) NS 22 (24) NS 17 (19) NS 16 (18) NS
Female 65 30 (46) 34 (52) 24 (37) 14 (22) 10 (15) 23 (35) 18 (28) 16 (25) 9 (4)
Site
Colon 106 45 (42) NS 52 (49) NS 34 (32) NS 29 (27) NS 20 (19) NS 40 (38) NS 25 (24) NS 23 (22) NS 19 (18) NS
Rectum 49 26 (53) 27 (55) 16 (33) 12 (24) 10 (20) 24 (49) 15 (31) 10 (20) 6 (12)
Depth
pT1 12 4 (33) 0.03 4 (33) 0.004 0 0.003 1 (8) NS 0 0.015 1 (8) 0.003 0 0.015 0 0.004 0 0.009
pT2 29 8 (28) 7 (24) 4 (14) 5 (17) 5 (17) 6 (21) 4 (14) 1 (3) 0
pT3 105 52 (50) 62 (59) 42 (40) 30 (29) 20 (19) 52 (50) 35 (33) 31 (30) 24 (23)
pT4 9 7 (78) 6 (67) 4 (44) 5 (56) 5 (56) 5 (56) 1 (11) 1 (11) 1 (11)
Lymphatic invasion
Negative 31 9 (29) 0.044 11 (35) NS 8 (26) NS 7 (23) NS 4 (13) NS 12 (39) NS 8 (26) NS 3 (10) NS 3 (10) NS
Positive 124 62 (50) 68 (55) 42 (39) 34 (27) 26 (21) 52 (42) 32 (26) 30 (24) 22 (18)
Vascular invasion
Negative 61 24 (39) NS 25 (41) 0.05 12 (20) 0.008 15 (25) NS 10 (16) NS 19 (31) 0.046 8 (13) 0.005 10 (16) NS 7 (11) NS
Positive 94 47 (50) 54 (57) 38 (40) 26 (28) 20 (21) 45 (48) 32 (34) 23 (24) 18 (19)
Lymph node status
pN0 85 37 (44) NS 35 (41) 0.01 18 (21) 0.002 18 (21) NS 11 (13) 0.04 34 (40) NS 18 (21) NS 18 (21) NS 15 (18) NS
pNx 70 34 (49) 44 (63) 32 (46) 23 (33) 19 (27) 30 (43) 22 (31) 15 (21) 10 (14)
TNM stage
I 35 11 (31) 0.023 9 (26) <0.001 3 (9) <0.001 5 (14) 0.033 4 (11) 0.031 7 (20) 0.026 3 (8) 0.041 1 (3) <0.001 0 0.005
II 43 21 (49) 20 (47) 11 (26) 9 (21) 4 (9) 21 (49) 11 (26) 13 (30) 11 (26)
III 53 22 (42) 31 (58) 20 (38) 16 (31) 14 (26) 23 (43) 17 (32) 8 (15) 7 (13)
IV 24 17 (71) 19 (79) 16 (67) 11 (46) 8 (33) 13 (54) 9 (38) 11 (46) 7 (29)
Liver metastatis
Negative 133 55 (41) 0.001 62 (47) 0.01 35 (26) <0.001 30 (23) 0.016 22 (17) 0.041 52 (39) NS 32 (24) NS 22 (17) 0.001 18 (14) NS

















Table 1 Relationship between heregulin, ErbB1-4, pErbB1-4 and clinicopathological factors (Continued)
Recurrence
Negative 119 51 (43) NS 55 (46) 0.037 29 (24) <0.001 28 (24) NS 19 (16) NS 40 (34) 0.001 21 (18) <0.001 18 (15) 0.002 12 (10) 0.001

















Table 2 Univariate and multivariate Cox proportional hazards analysis for disease-free survival (Stage ll-lll) (N = 95)
Variables Categories Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Depth (T factor) T2 vs. T3, T4 1.40 (0.82-2.38) NS
Lymph node status Positive vs. negative 2.55 (1.25-5.20) 0.01 3.46 (1.50-7.97) 0.004
Heregulin expression Positive vs. negative 2.03 (1.04-3.94) 0.037 1.72 (0.83-3.55) NS
EGFR expresion Positive vs. negative 1.76 (0.88-3.51) NS
pEGFR expression Positive vs. negative 4.08 (2.08-8.01) <0.001 2.06 (0.94-4.55) NS
ErbB2 expression Positive vs. negative 1.83 (0.93-3.62) NS
pErbB2 expression Positive vs. negative 2.90 (1.44-5.81) 0.003 1.05 (0.47-2.34) NS
EbB3 expression Positive vs. negative 2.24 (1.14-4.44) 0.02 1.31 (0.61-2.85) NS
pErbB3 expression Positive vs. negative 3.76 (1.95-7.28) <0.001 2.60 (1.06-6.37) 0.036
ErbB4 expression Positive vs. negative 2.27 (1.15-4.49) 0.018 0.69 (0.21-2.35) NS
pErbB4 expression Positive vs. negative 3.41 (1.25-5.20) <0.001 5.24 (1.50-7.97) 0.01
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pErbB2, ErbB3, pErbB3, ErbB4 and pErbB4 each had sig-
nificant prognostic value (Table 3). In multivariate ana-
lysis performed by introducing all the above variables in
the Cox proportional hazards model, lymph node status,
pEGFR and pErbB4 retained independent prognostic sig-
nificance (Table 3, Figure 3). Similar results were ob-
tained for stage II-IV stage patients (data not shown).
Discussion
We examined the expression, localization, and clinical
significance of heregulin, EGFR, pEGFR, ErbB2, pErbB2,
ErbB3, pErbB3, ErbB4 and pErbB4 in CRC. Although
there have been a number of reports regarding the ex-
pression of ErbB family members in CRC, there have
been few studies targeting the phosphorylated ErbB
family members; furthermore, the number of cases ex-
amined in those studies was relatively small and theTable 3 Univariate and multivariate Cox proportional hazards
Variables Categories Un
HR (95% C
Depth (T factor) T1, T2 vs. T3, T4 1.78 (0.95-3
Lymph node status Positive vs. negative 5.32 (2.75-1
Heregulin expression Positive vs. negative 2.22 (1.23-4
EGFR expression Positive vs. negative 2.31 (1.25-4
pEGFR expression Positive vs. negative 3.93 (2.19-7
ErbB2 expression Positive vs. negative 1.95 (1.08-3
pErbB2 expression Positive vs. negative 2.29 (1.23-4
ErbB2 expression Positive vs. negative 2.33 (1.30-4
pErbB3 expression Positive vs. negative 2.46 (1.37-4
ErbB4 expression Positive vs. negative 2.99 (1.67-5
pErbB4 expression Positive vs. negative 3.84 (2.11-6association with patient prognosis was not elucidated
[28]. We examined the relationship between the expression
of phosphorylated ErbB family members and clinicopatho-
logical characteristics of CRC patients using a relatively
large number of cases. As a result, we have shown that
EGFR, ErbB2, ErbB3 and ErbB4 expression in CRC pa-
tients was positive in 51%, 26%, 36% and 21% cases, re-
spectively, consistent with previous reports. In addition, we
found positive pEGFR, pErbB2, pErbB3 and pErbB4 ex-
pression in 32%, 21%, 18% and 16% of CRC patients, re-
spectively. Notably, pEGFR, pErB2 and pErbB3 localized in
the nuclei of CRC cells; and we found for the first time that
pEGFR, pErbB2, pErbB3 and pErbB4 correlated with
poorer patient prognosis.
We found that heregulin is expressed exclusively in
colorectal cancer cells. This is inconsistent with a recent
paper, in which heregulin was expressed exclusively in
mesenchymal cells of CRC tissues [24]. Although we didanalysis for overall survival (stage l-lV) (N = 155)
ivariate analysis Multivariate analysis
I) P value HR (95% CI) P value
.53) NS
0.32) <0.001 6.27 (2.94-13.36) <0.001
.01) 0.008 1.81 (0.94-3.46) NS
.27) 0.007 0.45 (0.16-1.27) NS
.05) <0.001 2.85 (1.05-7.73) 0.04
.51) 0.027 0.59 (0.16-2.15) NS
.24) 0.008 1.78 (0.47-6.72) NS
.18) 0.005 1.75 (0.87-3.53) NS
.41) 0.003 1.12 (0.53-2.38) NS
.37) <0.001 1.42 (0.55-3.65) NS
.99) <0.001 2.59 (1.01-6.69) 0.049
Figure 3 Kaplan-Meier overall survival curve for pEGFR expression (A) and pErbB4 expression (B) in stage l-lV patients.
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http://www.biomedcentral.com/1471-2407/14/863not exclude the possibility of heregulin expression in
mesenchymal cells, we believe that heregulin originating
from cancer cells mainly contribute to tumorigenesis.
Previous studies have reported that interleukin-1, prosta-
glandin E2, hepatocyte growth factor and keratinocyte
growth factor can upregulate the expression and secre-
tion of heregulin in epithelial cells [29]. We have already
examined heregulin expression using a number of cancer
cell lines and biopsy specimens of colorectal cancer tis-
sues and found that cancer epithelial cells themselves ex-
press heregulin in situ [23]. In addition, we found that
heregulin and vascular endothelial growth factor coloca-
lized in cancer epithelial cells in CRC patients. Other
investigators also have shown that heregulin is co-
expressed with ErbB2 expression in colon cancer speci-
mens and that autocrine activation of ErbB2 occurs
through dimerization to ErbB3 in a colon carcinoma cell
line [30]. This suggests that autocrine heregulin/ErbB
family loops may be important modulators of aberrant
growth in colon cancer.
Although EGFR is the only ErbB family member with
a clinically validated role in CRC, there is a wide vari-
ation in the expression level (from 8 to 100%) of EGFR
and there is no data regarding pEGFR localization by
immunohistochemical analysis [4]. Also, there are con-
flicting data on its prognostic significance [31]. Here, we
show that pEGFR but not EGFR expression correlated
with worse patient overall survival rate both in univari-
ate and multivariate analysis using the Cox proportional
hazards model.
Several studies have reported the overexpression of
ErbB2 in CRC and there is a wide variation in the
expression level of ErbB2 [4,32]. Furthermore, unlike
breast cancer, heterogeneous ErbB2 immunostaininghas been reported in CRC [33]. Conradi et al. concluded
that ErbB2 status should ideally be analyzed on represen-
tative slides of the resected tumor and that biopsy sam-
ples may not be sufficient [32]. We used representative
slides of surgically resected CRC samples to avoid sam-
pling error due to small sample size.
ErbB2 is detected in the cytoplasmic fraction of
Caco-2 cells in steady state. However, when Caco-2 cells
are stimulated with exogenous heregulin, pErbB2 is de-
tected in the nuclear fraction as well as in the cytoplasm
fraction of these cells. In fact, immunohistochemical ana-
lysis has detected positive pErbB2 expression both in the
cytoplasm and nucleus of CRC tissues. This suggests that
ErbB2 localized in the cell membrane translocates par-
tially to the nucleus via ligand stimulation. Therefore, we
did not consider ErbB2 in the cytoplasm and nuclei of
cancer cells as positive; rather, we determined pErbB2 in
the cytoplasm and nuclei of these cells to be positive.
As a result, we found that pErbB2 but not ErbB2 sig-
nificantly correlated with disease free survival of CRC
patients. These results suggest that ErbB2 phosphory-
lated through dimerization to ErbB3 stimulated by here-
gulin accounts for the aggressive behavior of CRC cells.
ErbB3 was found by immunohistochemical analysis to
be localized mainly in the cell membrane of CRC cells,
consistent with a recent report [34]. On the other hand,
pErbB3 was found exclusively in the nucleus of CRC cells.
There have been few studies regarding the localization of
pErbB3 in CRC [28]. Those studies reported that pErbB3
was observed in the nucleus of CRC cells in 22.7% cases,
which is consistent with our data. We examined whether
ErbB3 or pErbB3 expression is related to patient progno-
sis. Previous data is controversial; Baiocchi et al. have
shown that ErbB3 expression is related to better overall
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studies [34-36]. Using ErbB3 knockdown mice, Lee et al.
have shown that ErbB3 has essential roles in supporting
intestinal tumorigenesis and suggest that ErbB3 may be a
promising target for the treatment of colorectal cancers
[9]. We show that pErbB3 but not ErbB3 expression corre-
lated with worse patient disease free survival rate both in
univariate and multivariate analysis using the Cox propor-
tional hazards model.
There have been a few reports concerning ErbB4 in
CRC tumorigenesis. There have been only four studies
on ErbB4 expression patterns and prognostic signifi-
cance in CRC patients [36-39]. Baiocchi et al. examined
109 stage II-III CRC patients for the expression levels of
EGFR to ErbB4 and found membranous positive ErbB4
expression as an independent prognostic factor for re-
currence, while other researchers did not find any
significant relationship between ErbB4 expression and
patients prognosis. There has been no report to date
concerning pErbB4 expression patterns and prognostic
significance in CRC patients. In the present study, we
found for the first time that both ErbB4 and pErbB4 posi-
tivity is significantly related with worse prognosis. In par-
ticular, we show that pErbB4 expression correlated with
worse patient disease overall survival rate in multivariate
analysis using the Cox proportional hazards model inde-
pendent of pEGFR expression or lymph node metastasis.
This suggests that the heregulin-ErbB4 loop affects CRC
patients’ prognosis to the same degree as that of EGFR
activation.
It appears that ErbB4 protein expression is difficult to
detect in cultured cancer cell lines although there have
been a few reports that ErbB4 can be detected in certain
CRC cell lines [27]. In fact, we also have reported that
ErbB4 is almost negative in the cytosolic fractions of two
CRC cell lines examined, DLD-1 and Caco-2 [23]. This
corresponds with the fact that few CRC cell lines express
ErbB4. In the present study, we chose HCT 116 accord-
ing to a previous report [27]. In addition, we used con-
centrated protein lysate to detect ErbB4 protein more
effectively. As a result, we have shown that both ErbB4
and pErbB4 stimulated by heregulin can be detected in
the cytoplasm of HCT 116 cells.
Accumulating evidence suggests that EGFR translo-
cates to the nucleus both in normal and cancer cells
alike. Nuclear EGFR has been identified in various
tumor tissues, including breast cancer, ovarian cancer, and
oropharyngeal and esophageal squamous cell carcinomas,
and has been shown to be associated with poor patient
outcomes [40]. Here, we show, by immunoprecipitaion
and western blot analysis, that ligands stimulate the trans-
location of ErbB2 and ErbB3 into the nucleus in CRC
cells. The molecular weight of pErbB2 and pErbB3 in the
nuclear fraction was approximately 180 kD, correspondingto the molecular weight of the full-length ErbB2 (185 kD)
and ErbB3 (180 kD). The DLD-1 cells express EGFR,
ErbB2, and ErbB3 strongly. On the other hand, The Caco-
2 cells express ErbB2 and ErbB3 weakly, and EGFR nega-
tive. pErbB2 was observed without heregulin stimulation
in the nuclear fractions of DLD-1 cells, whereas pErbB2
and pErbB3 were detected in the nuclear fractions of
Caco-2 cells only after heregulin stimulation. These results
suggest that heregulin stimulated ErbB2 and ErbB3 phos-
phorylation in the nuclear fractions without participation
of the EGFR signal crosstalks since Caco-2 cells express
low levels of EGFR [23]. These data suggest that, in
addition to EGFR, ErbB2 or ErbB3 itself may play a role as
a signal transduction mediator. Unlike EGFR and ErbB2,
ErbB3 has been known as a kinase-inactive member of the
EGFR family, which lacks the ability of signal transduction
without ErbB2 or ErbB4. However, our immunohisto-
chemical analysis has shown that ErbB3 does not always
colocalize with ErbB2 or ErbB4. Thirty-one cases (20%)
were positive for only ErbB3. Therefore, it is reasonable to
consider that ErbB3 alone may play a role via its transloca-
tion to the nucleus of cancer cells, where it can target a
particular gene to induce the expression of a specific
oncoprotein.
Conclusions
We have shown that phosphorylated ErbB2 and ErbB3
stimulated by heregulin, localized in the nucleus of CRC
cells. Phosphorylated EGFR, ErbB2, ErbB3, ErbB4 and their
relevant growth factor heregulin contribute to worse pa-
tient prognosis in CRC. This heregulin-ErbB family mem-
ber autocrine loop may be a candidate target of CRC
therapy as well as EGFR. Further investigation is clearly
warranted to elucidate the role of nuclear phosphorylated
ErbB2 and ErbB3 in CRC.
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